Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

871 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-10

Study Completion Date

2020-08-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic kidney disease (CKD) and hypertension are two closely related common chronic diseases that have serious implications to human health. Hypertension is a major cause for progression of renal disease and a risk factor for cardiovascular disease (CVD). Control of Blood Pressure (BP) to target is now considered to be the main goal in the treatment of patients with CKD.

In clinical practice, it is difficult for CKD patients with hypertension to achieve systolic BP (SBP) or diastolic BP (DBP) goal; oftentimes, calcium channel blocker (CCB) class of drugs, for example, nifedipine gastrointestinal therapeutic system (GITS), is used in such patients. Previous data have demonstrated nifedipine to be having a significant dose-response relationship; that is, nifedipine 60 mg provided better BP reduction than 30 mg. However, there are limited studies that have evaluated the efficacy and tolerability of nifedipine GITS 60 mg in Chinese CKD patients with hypertension. Hereby, the objective of this study was to evaluate the effectiveness and tolerability of nifedipine GITS 60 mg treatment in a large cohort of CKD patients with uncontrolled hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Dietary Nitrate in Patients With Hypertensive Kidney Injury

NCT07290842

Hypertension CKD - Chronic Kidney Disease

RECRUITING NA

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

NCT01658657

Hypertension Plasma Renin Activity

COMPLETED NA

Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension

NCT06783296

Hypertension Renal Denervation Therapy

NOT_YET_RECRUITING NA

Potassium Supplementation in CKD

NCT03253172

Renal Insufficiency, Chronic Potassium Depletion Hypertension +1 more

ACTIVE_NOT_RECRUITING NA

Blood Pressure in Dialysis Patients

NCT01421771

Hypertension Renal Failure Chronic Requiring Hemodialysis Blood Pressure +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)

Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.

Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)

Intervention Type DRUG

Nifedipine GITS 60 mg (once per day)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)

Nifedipine GITS 60 mg (once per day)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients aged 18-70 years
* Patients diagnosed with CKD (Estimated Glomerular Filtration Rate (eGFR) \>15 mL/min/1.73 m\*2) and hypertension without dialysis/replacement therapy
* Patients with uncontrolled hypertension (office SBP ≥140 mmHg and DBP ≥ 80 mmHg) who have received Renin-Angiotensin System Inhibitors (RASI) treatment or have not received RASI treatment because of any contraindications
* Patients who haven't received nifedipine GITS 60 mg (once per day) previously
* Patients for whom the decision to initiate treatment with nifedipine GITS 60 mg was made as per the investigator's routine treatment practice
* Signed informed consent
* No participation in an investigational program with interventions outside of routine clinical practice

Exclusion Criteria

* Have a contraindication to nifedipine GITS according to the approved prescribing information
* Patients participating in an investigational program with interventions outside of routine clinical practice

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No